Insights into osteoporosis treatments as societies around the world age.
Search results for: bisphosphonate
Biosimilars to Denosumab Approved with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab.
Case Report: Complicated Presentation Eventually Explained by Rare Syndrome
Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…
To the Bone: Experts Discuss Developments in Osteoporosis Care
During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.
The Eyes Have It
SAN DIEGO—Many rheumatologists see patients referred for uveitis, and Laura Kopplin, MD, PhD, assistant professor of ophthalmology and visual sciences, University of Wisconsin, Madison, discussed inflammatory disease of the eye at ACR Convergence 2023.
ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline
The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…
Glucocorticoid Use at Any Dose Increases Fracture Risk
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
Highlights from the ACR Review Course 2022
PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….
A Clear Vision: Understanding the Connection Between Ophthalmology & Rheumatic Disease
Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
Challenging Cases in Osteoporosis: Tips from an Expert
Using three complicated patient cases, Kenneth G. Saag, MD, MSc, shared his expertise on osteoporosis and walked through his thought process and the literature, during a session of the 2022 ACR Education Exchange.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »